Global Sandostatin LAR Drugs Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Sandostatin LAR Drugs Market Insights, Forecast to 2034
Octreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone.
Global Sandostatin LAR Drugs market is expected to reach to US$ 1038 million in 2024, with a positive growth of %, compared with US$ 1238 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Sandostatin LAR Drugs industry is evaluated to reach US$ 680.3 million in 2029. The CAGR will be -6.8% during 2024 to 2029.
The Sandostatin LAR market analysis reveals a specialized segment within the pharmaceutical industry. Sandostatin LAR is a long-acting formulation of octreotide, a synthetic hormone used to treat various neuroendocrine tumors and acromegaly. The market growth is driven by the increasing prevalence of these conditions and the efficacy of Sandostatin LAR in managing symptoms and slowing tumor growth. Additionally, advancements in drug delivery technologies contribute to its popularity. However, competition from other somatostatin analogs and the high cost of treatment may impact market penetration. Despite challenges, the Sandostatin LAR market holds promise as healthcare providers prioritize personalized and targeted therapies for neuroendocrine disorders, creating opportunities for further development and investment.
Report Covers
This report presents an overview of global Sandostatin LAR Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Sandostatin LAR Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Novartis
Segment by Type
500mcg
1000mcg
Other
Tumors
Bleeding Esophageal Varices
Other
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Sandostatin LAR Drugs plant distribution, commercial date of Sandostatin LAR Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Sandostatin LAR Drugs introduction, etc. Sandostatin LAR Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Sandostatin LAR Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Sandostatin LAR Drugs market is expected to reach to US$ 1038 million in 2024, with a positive growth of %, compared with US$ 1238 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Sandostatin LAR Drugs industry is evaluated to reach US$ 680.3 million in 2029. The CAGR will be -6.8% during 2024 to 2029.
The Sandostatin LAR market analysis reveals a specialized segment within the pharmaceutical industry. Sandostatin LAR is a long-acting formulation of octreotide, a synthetic hormone used to treat various neuroendocrine tumors and acromegaly. The market growth is driven by the increasing prevalence of these conditions and the efficacy of Sandostatin LAR in managing symptoms and slowing tumor growth. Additionally, advancements in drug delivery technologies contribute to its popularity. However, competition from other somatostatin analogs and the high cost of treatment may impact market penetration. Despite challenges, the Sandostatin LAR market holds promise as healthcare providers prioritize personalized and targeted therapies for neuroendocrine disorders, creating opportunities for further development and investment.
Report Covers
This report presents an overview of global Sandostatin LAR Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Sandostatin LAR Drugs market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Novartis
Segment by Type
500mcg
1000mcg
Other
Segment by Application
Tumors
Bleeding Esophageal Varices
Other
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
UK
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Sandostatin LAR Drugs plant distribution, commercial date of Sandostatin LAR Drugs, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Sandostatin LAR Drugs introduction, etc. Sandostatin LAR Drugs Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Sandostatin LAR Drugs
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices